-
Mosaic Therapeutics In-Licenses Two Clinical-Stage Oncology Programs From Astex Pharmaceuticals for Development as Proprietary Combination Therapies
24 Apr 2025 07:29 GMT
… or ‘the Company’) a targeted oncology therapeutics company dedicated to resolving … of two clinical-stage oncology programs from Astex Pharmaceuticals (‘Astex’), a wholly owned … identifies combinations of pairs of oncology drugs predicted to have synergistic …
-
GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion | DelveInsight
30 Jun 2025 22:32 GMT
… .
In July 2024, Radionetics Oncology entered into a strategic agreement … the role of GPCRs in oncology, metabolic disorders, and immune … CStone Pharmaceuticals, Affimed, Otsuka Pharmaceutical, Astex Pharmaceuticals, Autolus, Myeloid Therapeutics, Merck Sharp …
-
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
13 May 2025 11:11 GMT
… president and head of oncology, global clinical development, … Pharmaceutical Co. Ltd and Astex Pharmaceuticals (UK), a wholly … European Network for Gynaecological Oncology Trial (ENGOT) groups … industry’s largest immuno-oncology clinical research program. …
-
Mosaic Therapeutics In-Licenses Two Clinical-Stage Oncology Programs from Astex
29 Apr 2025 19:17 GMT
… of two clinical-stage oncology programs from Astex Pharmaceuticals. Mosaic has identified proprietary … identifies combinations of pairs of oncology drugs predicted to have synergistic …
-
Mosaic Therapeutics in-licenses two clinical-stage oncology programs
28 Apr 2025 12:27 GMT
Mosaic Therapeutics, a targeted oncology therapeutics company dedicated to … of two clinical-stage oncology programs from Astex Pharmaceuticals, a wholly owned subsidiary … identifies combinations of pairs of oncology drugs predicted to have synergistic …
-
Astex Pharmaceuticals Announce Key Data Presentations At The 36Th EORTC-NCI-AACR Symposium
21 Oct 2024 08:34 GMT
… novel small molecule therapeutics for oncology and diseases of the … Agents
Presenter: Gianni Chessari, Astex Pharmaceuticals, UK Catalog #42
Presentation … Translational Studies
Presenter: Andrea Biondo, Astex Pharmaceuticals, UK
Catalog #289
Presentation # …
-
Astex Pharmaceuticals Announce Key Data Presentations at the 36th EORTC-NCI-AACR Symposium
21 Oct 2024 08:00 GMT
… small molecule therapeutics for oncology and diseases of the … Targeted Agents
Presenter: Gianni Chessari, Astex Pharmaceuticals, UK
Catalog #42
Presentation … Translational Studies
Presenter: Andrea Biondo, Astex Pharmaceuticals, UK
Catalog #289
Presentation …
-
Race Oncology secures A$5.25 million R&D tax rebate for FY2024
17 Dec 2024 00:57 GMT
… companies such as Race Oncology solve significant unmet needs … needs of patients across multiple oncology indications.
The company is … Race Oncology has formed collaborations with several leading institutions, including Astex Pharmaceuticals, City …
-
Astex Pharmaceuticals Announce Key Data Presentations at the American Association For Cancer Research (AACR) 2024 Annual Meeting
03 Apr 2024 11:00 GMT
… 03, 2024 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, a pharmaceutical company based in … novel small molecule therapeutics for oncology and diseases of the central … , Japan. For more information about Astex Pharmaceuticals please visit: http:/…
-
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
24 Oct 2024 06:39 GMT
… NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for breast … under a research collaboration with Astex Pharmaceuticals.
Please see full Prescribing Information … nccn-clinical-practice-guidelines-in-oncology-nccn-guidelines-302285509.html
…
About
© 1995-2025